The Company recorded substantial growth in Revenue (up by 21 per cent over previous corresponding quarter) and in EBITDA at Rs 109 crore compared to a nominal profit of Rs 27 crore in the corresponding quarter of the previous year.
The company got approval from the capital market regulator SEBI on October 29 for the initial public offering. It will raise Rs 150 crore fresh capital, while 1.32 crore shares will be on offer for sale from promoters and a private equity investor. There is no company in India into PCR and cell/tiss
J&J said in a filing with the U.S. Securities and Exchange Commission on Friday that it reached a settlement in principle in September to resolve 'substantially all' of the roughly 9,000 cases that the New Brunswick, New Jersey-based drugmaker faced over Risperdal.
The weaker-than-expected growth reported by the Commerce Department on Thursday also reflected decreasing pandemic relief money from the government to businesses, state and local governments as well as households.
The money will support efforts to develop and make generic versions of what could become the first oral antiviral medication for the disease if it wins regulatory approval, the foundation said in a statement.